12 results match your criteria: "National Blood Transfusion Centre of Tunis[Affiliation]"
Lab Med
January 2025
Immunogenetics, Cell Therapy and Blood Transfusion Research Laboratory (LR20SP05), Department of Immunohaematology, National Blood Transfusion Centre of Tunis, University of Tunis El Manar, Tunis, Tunisia.
Background: The presence of some red blood cell (RBC) antigens may affect the preference for using type O blood in emergency situations because they may induce complex or multiple alloimmunization in special circumstances.
Methods: A subgroup of 77 type O blood Tunisian donors were genotyped for 19 common blood alleles using the single specific primer-polymerase chain reaction method. The statistical analysis was done using HaploView software.
Hum Immunol
September 2024
"Immunogenetics, cell therapy and blood transfusion" research laboratory (LR20SP05), National Blood Transfusion Centre of Tunis, University of Tunis El Manar. Tunisia.
Graft-versus-host disease (GVHD) is a potentially serious complication ofallogeneic hematopoietic stem cell transplantation (HSCT). Graft-contaminating T cells (donor T cells) arecrucial for the development ofGVHD since they are able to react against the recipient's antigens. In this study we aim toevaluatethepotentialassociation between the IVS3 + 17 T/C gene variation in the CD28 molecule, a T cells costimulatory factor, and the GVHD occurrence in a Tunisian group of recipients of allo-HSCTs.
View Article and Find Full Text PDFTransfus Clin Biol
February 2021
Dubai Blood Donation Centre, Dubai Health Authority, Dubai, United Arab Emirates. Electronic address:
Background: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has spurred a global health crisis. The safety and supply of blood during this pandemic has been a concern of blood banks and transfusion services as it is expected to adversely affect blood system activities. We aim to assess the situation in the Eastern Mediterranean Region (EMR) during the first months of the pandemic.
View Article and Find Full Text PDFHum Immunol
March 2019
Immunogenetic Applied to Cells Therapy Research Unit, Immuno-Haematology and HLA-Typing Department, National Blood Transfusion Centre of Tunis, Tunis, Tunisia.
Bronchiolitis obliterans (BO) is a serious lung complication that can develop after allogenic stem cell transplantation. It has been suggested that single nucleotide polymorphisms (SNPs) that affect the NOD2/CARD15 gene impair its function and result in an uncontrolled innate immune response in the recipient, thereby leading to BO. One hundred eighty-one donor-recipient pairs were analyzed for the association between NOD2 gene variants (SNP8 [Arg702Trp], SNP12 [Gly908Arg], and SNP13 [Leu1007fsinsC]) and the occurrence of BO.
View Article and Find Full Text PDFBiol Blood Marrow Transplant
December 2018
Department of Haematology, National Bone Marrow Transplantation Centre of Tunis, Tunis, Tunisia; Faculté de Médecine de Tunis, Université de Tunis El Manar, Tunis, Tunisia.
Human recombinant granulocyte colony stimulating factor reduces the duration of neutropenia following HLA-identical allogeneic bone marrow transplantation. However, its use remains controversial due to the risk of increasing the incidence of acute graft-versus-host disease (GVHD) and slower platelet recovery. To clarify these risks, we conducted a prospective randomized placebo-controlled trial of filgrastim 5 µg/kg/day i.
View Article and Find Full Text PDFTranspl Immunol
September 2011
The "Immunogenetic Applied to Cells Therapy" Research Unit, The Immunohaematology and HLA-Typing Department, National Blood Transfusion Centre of Tunis, 1006 Tunis, Tunisia.
Chemokine receptors are very important players in the pathogenesis of GVHD. The aim of this study is to test the hypothesis that the lack of expression of the DARC receptor on erythrocytes can affect the GVHD incidence. A total of 105 recipients and their 105 respective sibling donors of HSCs were enrolled in this study.
View Article and Find Full Text PDFDNA Cell Biol
March 2012
The Immunogenetic Applied to Cells Therapy Research Unit, The Immunohaematology and HLA-Typing Department, National Blood Transfusion Centre of Tunis, Tunis, Tunisia.
FY antigens are candidate minor histocompatibility antigens relevant to renal allograft rejection, but no data have been reported about their role in graft-versus-host disease (GVHD) incidence after human leukocyte antigen (HLA)-identical siblings hematopoietic stem cell transplantation (HSCT). The aim of this study was to examine the effect of donor/recipient disparity at FY antigens on the incidence of GVHD in Tunisian patients receiving an HLA-identical HSCT. This work enrolled 105 Tunisian pairs of recipients and their HLA-identical sibling donors of HSCs.
View Article and Find Full Text PDFClin Biochem
June 2011
The Immunogenetic applied to cells therapy Research Unit, The Immunohaematology and HLA-Typing Department, National Blood Transfusion Centre of Tunis, 1006 Tunis, Tunisia.
Objective: The aim of this study is to examine the effect of donor PECAM-1 alleles and haplotypes for the SNPs L98V, S536N, and R643G on the occurrence of GVHD in Tunisian recipients of HSCs.
Design And Methods: This study enrolled 102 patients and their 102 respective HLA-identical sibling donors of HSCs. The PECAM-1 SNPs genotyping assay was performed using sets of sequence specific primers (SSP-PCR).
Clinics (Sao Paulo)
October 2011
HLA-Typing Department, National Blood Transfusion Centre of Tunis, Tunisia.
Introduction: Minor histocompatibility antigen HA-1 (MiHAg-HA-1) disparity between a patient and his or her human leukocyte antigen (HLA) genoidentical donor has been widely associated with an increased risk of graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
Objective: To examine the effect of HA-1 disparity on the incidence of both acute and chronic graft-versus-host disease in Tunisian recipients of hematopoietic stem cells.
Methods: A total of 60 patients and their 60 respective sibling hematopoietic stem cell donors were enrolled in this study.
Hum Immunol
February 2011
Immunogenetic applied to cells therapy Research Unit, Immunohaematology and HLA-Typing Department, National Blood Transfusion Centre of Tunis, Tunis, Tunisia.
The CTLA-4 genetic variation, such as single nucleotide polymorphisms (SNPs) may be critical and can affect the functional activity of cells that initiate the graft-versus-host disease (GVHD) effects. The aim of this study is to examine the effect of donor CTLA-4 alleles and haplotypes for the -318C>T and the 49A>G polymorphisms on the occurrence of GVHD in Tunisians recipients of HSCs. A total of 112 patients and their 112 respective sibling donors of HSCs were enrolled in this study.
View Article and Find Full Text PDFCell Immunol
November 2010
The "Immunogenetic Applied to Cells Therapy" Research Unit, The Immuno-Haematology Department, National Blood Transfusion Centre of Tunis, Tunisia.
GVHD is the major cause of mortality after HLA-identical HSCT. Such complication has been widely linked to donor/recipient disparity for minor histocompatibility antigens (MiHAgs). PECAM-1 is one of potential human MiHAgs but its effect on the GVHD occurrence remains not clear.
View Article and Find Full Text PDFImmunol Invest
December 2010
National Blood Transfusion Centre of Tunis, Immunohaematology, Bab Saadoun, Tunis, 1006 Tunisia.
Graft-versus-Host disease (GVHD) has been widely linked to immunogenetic causes such as disparity between the recipient and its HLA geno-identical donor for some Non-HLA antigens called minor histocompatibility antigens (MiHAgs). HA-2 is one of potential human MiHAgs but its effect on the GVHD occurrence remains not clear. In order to examine such association in the Tunisian cohort of HSCs recipients, we performed a retrospective study on patients who received an HLA-identical HSCT between 2000 and 2009.
View Article and Find Full Text PDF